ArticleNeuropsychiatric disease and treatment2026
An Open-Label, Single-Arm Trial of Transcranial and Intranasal Photobiomodulation in Patients with Schizophrenia: A Study Protocol.
Article in Neuropsychiatric disease and treatment, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Photobiomodulation (PBM) may alleviate cognitive disturbances in neurological and psychiatric disorders, potentially via improvements in brain metabolism and cerebral blood flow. This non-invasive approach may be beneficial for cognitive impairment associated with schizophrenia (CIS). We present a study protocol for an open-label trial evaluating the safety and tolerability of PBM in patients with schizophrenia. Patients and Methods: Patients with CIS will be recruited and receive PBM for 12 weeks (three sessions per week, 20 minutes per session). Eligibility criteria include a DSM-5 diagnosis of schizophrenia, age 18-70 years, and having marked cognitive impairment (≤-0.5 SD on the WAIS Digit Symbol Coding or Rey Auditory Verbal Learning Test). A total of 25 participants will be enrolled. Near-infrared light will be delivered using a multi-site system with transcranial and intranasal applicators. The primary outcome is safety and tolerability, assessed by the incidence and frequency of adverse events at baseline and at 1 week, 3 months, and 6 months after treatment initiation. Secondary outcomes include neurocognitive function, activities of daily living, social functioning, psychiatric symptoms, event-related potentials, and cerebral blood flow measured by near-infrared spectroscopy. Conclusion: This study will provide preliminary data on the safety and tolerability of PBM in Japanese patients with schizophrenia and explore its potential effects on CIS, informing future clinical trials. Ethics and Dissemination: The protocol was approved by the Clinical Research Review Board of the National Center of Neurology and Psychiatry (CR24-003) and registered with the Japan Registry of Clinical Trials (jRCT032240756).
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.